On Friday, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)’s shares inclined 2.11% to $4.36.
Arena Pharmaceuticals, Inc. (ARNA) declared that the following poster regarding lorcaserin HCl will be presented at American Diabetes Association’s 75th Scientific Sessions taking place June 5-9, 2015, in Boston, Massachusetts:
This post-hoc analysis evaluated the impact of sulfonylurea use on weight loss and glycemic parameters achieved with lorcaserin in patients with type 2 diabetes mellitus over 52 weeks.
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors. The company offers BELVIQ, a drug used to treat chronic weight administration in adults. It is also developing a portfolio of programs in various therapeutic areas, counting cardiovascular, central nervous system, and metabolic diseases. Its products under development comprise Ralinepag, an agonist of the prostacyclin receptor intended for the treatment of vascular diseases, counting potentially pulmonary arterial hypertension that is in Phase II clinical trials.
Zogenix, Inc. (NASDAQ:ZGNX)’s shares gained 4.14% to $1.76.
Zogenix, Inc. (ZGNX) a pharmaceutical company developing and commercializing unique therapies for the treatment of central nervous system (CNS) disorders, recently declared new data demonstrating sustained efficacy and tolerability for patients treated with low-dose fenfluramine as an adjunctive therapy for Dravet syndrome. The data was authored by world-renown experts in the field of Dravet syndrome, Berten Ceulemans, M.D., Ph.D. and Lieven Lagae, M.D., Ph.D., from the Universities of Antwerp and Leuven in Belgium, and was presented at the European Paediatric Neurology Society meeting taking place this week in Vienna, Austria (see study data here). Zogenix intends to initiate Phase 3 clinical studies for ZX008, the Company’s investigational proprietary pediatric formulation of low-dose fenfluramine, during the second half of 2015. ZX008 is designated as an orphan drug in both the U.S. and Europe for the treatment of Dravet syndrome.
Patients with Dravet syndrome experience frequent, severe and potentially life-threatening seizures that typically start in the first year of life. These seizures do not respond to standard anti-epileptic medications and current treatment options are very limited.
At the end of Friday’s trade, United Technologies Corporation (NYSE:UTX)‘s shares dipped -0.12% to $117.00.
United Technologies Corporation (UTX) has launched the 5th annual Sikorsky Helicopter 2050 Program and Challenge, which asks children, ages 9-16, to create an eco-friendly helicopter of the future that addresses potential challenges of 2050.
The national competition kicked off June 1 and will run until October 15, 2015. The winner of the 2015 competition will receive the Igor Sikorsky Youth Innovator Award and a $1,000 scholarship. In addition, the young innovator will be flown to Sikorsky’s headquarters in Stratford, Connecticut, to tour the assembly lines of the iconic BLACK HAWK and SEAHAWK® military helicopters and meet with Sikorsky rotorcraft engineers.
United Technologies Corporation provides technology products and services to building systems and aerospace industries worldwide. Its Otis segment designs, manufactures, sells, and installs passenger and freight elevators, escalators, and moving walkways; modernization products to upgrade elevators and escalators; and maintenance and repair services.
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), ended its Friday’s trading session with -1.81% loss, and closed at $60.62.
Teva Pharmaceutical Industries Ltd (ADR) (TEVA) declared the launch of the generic equivalent to INTUNIV® (guanfacine) 1 mg, 2 mg, 3 mg, and 4 mg, in the United States. Guanfacine extended-release tablets are a nonstimulant medication for the treatment of attention deficit hyperactivity disorder (ADHD) that can be used alone, or as an add-on to stimulant medications.
ADHD is the most common neurobehavioral disorder diagnosed in children in the United States. ADHD affects 1 in 10 U.S. children and half of these children are diagnosed by the age of six.
“Guanfacine extended-release tablets join Teva’s current generic line of seven ADHD products,” commented Brendan O’Grady, President and CEO, North America Generic Medicines. “We recognize the need to make affordable generic treatment options accessible to patients with ADHD.”
INTUNIV® (guanfacine) 1 mg, 2 mg, 3 mg, and 4 mg, had total market sales of about $804 million in the United States, according to IMS data as of March 2015.
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers generic or branded generic medicines; specialized products, such as sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances; and active pharmaceutical ingredients.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
